Keytruda is set to lose exclusivity in 2028, meaning Summit may face competition from cheaper biosimilars. Meanwhile, other ...

Immutep believes its LAG-3 candidate eftilagimod alpha may have a path to approval in first-line head and neck cancer after ...

Merck & Co.‘s planned debut this fall of an injectable form of its breakthrough cancer treatment Keytruda will simplify care, ...

New Jersey-based pharmaceutical giant Merck is investing $1 billion in what company executives described as a continued ...

Amazon was struggling before mixed second-quarter results, but it has several attractive growth opportunities. Mounting ...

The S&P 500, the Dow Jones, and the NASDAQ all moved between 0.8% and 1% lower by mid-afternoon. Palantir (PLTR) stock ...

Merck is expanding domestic manufacturing with a $895 million investment in its Kansas factory, one of several major projects ...

Merck & Co/MSD has won approval in the US for PD-1 inhibitor Keytruda as a treatment for hepatocellular carcinoma (HCC), the most common form of liver cancer, opening up another front in its ...

Three Motley Fool contributors believe you can. Here's why they think Axsome Therapeutics (NASDAQ: AXSM), Iovance ...

U.S. pharmaceutical imports surged in March, exceeding $50 billion, as drugmakers stockpiled inventory in anticipation of ...

Keytruda is currently the only PD-1/PD-L1 inhibitor approved for advanced cervical cancer, one of the most common tumour types in women with 14,500 new cases diagnosed every year in the US, and ...